Drug Delivery System
Online ISSN : 1881-2732
Print ISSN : 0913-5006
ISSN-L : 0913-5006
Feature articles “DDS medicines and their clinical developments” Editor:Hiroshi Kikuchi
Development of lecithinized superoxide dismutase as a drug for IPF
Tohru Mizushima
Author information
JOURNAL FREE ACCESS

2013 Volume 28 Issue 3 Pages 221-228

Details
Abstract
Idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD) are thought to involve lung injury induced by reactive oxygen species (ROS), in particular superoxide anion. The enzyme, superoxide dismutase (SOD) catalyses the dismutation of superoxide anion to hydrogen peroxide. Lecithinized SOD (PC-SOD) has overcome a number of previous clinical limitations of SOD, including low tissue affinity and low stability in plasma. Recent animal studies suggest that PC-SOD is effective for the treatment of IPF and COPD. We are now performing the clinical study of PC-SOD for IPF patients.
Content from these authors
© 2013 Japan Society of Drug Delivery System
Previous article
feedback
Top